AcelRx Pharmaceuticals Inc  

(Public, NASDAQ:ACRX)   Watch this stock  
Find more results for ACRX
6.68
-0.51 (-7.09%)
May 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.50 - 7.26
52 week 2.27 - 7.30
Open 7.26
Vol / Avg. 337,468.00/314,033.00
Mkt cap 247.56M
P/E     -
Div/yield     -
EPS -1.50
Shares 37.06M
Beta     -
Inst. own 79%
Jun 4, 2013
AcelRx Pharmaceuticals, Inc. at Jefferies Global Healthcare Conference - 1:00PM EDT - Add to calendar
May 22, 2013
AcelRx Pharmaceuticals, Inc. at UBS Global Healthcare Conference - 9:30AM EDT - Add to calendar
May 8, 2013
Q1 2013 AcelRx Pharmaceuticals, Inc. Earnings Conference Call - Webcast
Mar 20, 2013
AcelRx Pharmaceuticals, Inc. at Roth Conference
Mar 12, 2013
Q4 2012 AcelRx Pharmaceuticals, Inc. Earnings Conference Call
Mar 6, 2013
AcelRx Pharmaceuticals, Inc. at Cowen Health Care Conference
Mar 5, 2013
AcelRx Pharmaceuticals, Inc. to Discuss the Phase 3 Top-Line Results - Conference Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin -628.18% -1393.61%
Operating margin -479.34% -1241.14%
EBITD margin - -1215.87%
Return on average assets -91.08% -63.33%
Return on average equity -251.81% -130.03%
Employees 25 -
Carbon Disclosure Rating - -

Address

351 Galveston Drive
REDWOOD CITY, CA 94063
United States - Map
+1-650-2163500 (Phone)
+1-650-2166500 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

AcelRx Pharmaceuticals, Inc. is a United States-based Pharmaceutical Company, which develops and commercializes therapies for the treatment of pain. The Company's products include ARX-01 Sufentanil NanoTab PCA System, to solve the problems associated with post-operative intravenous patient-controlled analgesia (IV PCA); ARX-02 Sufentanil NanoTab BTP Management System is a treatment option for cancer patients who suffer from breakthrough pain (BTP). ARX-03 Sufentanil/Triazolam NanoTab, provides non-invasive mild sedation, anxiety reduction and pain relief; and ARX-04 Sufentanil Acute Pain NanoTab, is a sublingual sufentanil product candidate designed to provide a non-invasive, fast-onset treatment of patients with moderate-to-severe acute pain, both on the battlefield and in civilian settings of trauma or injury.

Officers and directors

Adrian Adams Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Richard A. King President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
James H. Welch Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
Pamela P. Palmer M.D., Ph.D. Chief Medical Officer, Director
Age: 50
Bio & Compensation  - Reuters
Badri N. Dasu Chief Engineering Officer
Age: 49
Bio & Compensation  - Reuters
Lawrence G. Hamel Chief Development Officer
Age: 61
Bio & Compensation  - Reuters
Mark G. Edwards Independent Director
Age: 55
Bio & Compensation  - Reuters
Stephen J. Hoffman M.D., Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Guy P. Nohra Independent Director
Age: 52
Bio & Compensation  - Reuters
Howard B. Rosen Independent Director
Age: 54
Bio & Compensation  - Reuters